NG
NGL Fine Chem Ltd (NGLFINE)
₹3,050.00
Mkt cap
₹1,711 Cr
P/E ratio
33.90
P/B
5.89
Div yield
0.06%
ROE
15.60%
ROCE
16.70%
EPS (TTM)
₹89.97
Book value
₹518
52W range
1,271–3,602
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health. [1]
NSE NGLFINEBSE 524774
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−15.32% from high₹3,050
₹1,271+139.97% from low₹3,602
Current
₹3,050.00
Prev close
₹3,020.00
Day
+0.99%
Price performance
1D
+0.99%
1W
+11.72%
1M
+3.71%
3M
−1.37%
6M
+43.02%
1Y
+119.66%
YTD
+116.60%
Financials
Revenue, profit & margin
P/E ratio
33.9×
NGLFINE is 2% below the sector median of 34.6×
NGLFINE33.9×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 79 | 85 | 96 | 88 | 91 | 87 | 93 | 101 | 117 | 126 | 145 | 137 | |
| Expenses | 62 | 66 | 74 | 83 | 82 | 81 | 83 | 89 | 93 | 103 | 106 | 127 | 117 | |
| Operating Profit | 8 | 13 | 11 | 13 | 6 | 11 | 4 | 4 | 8 | 14 | 20 | 18 | 20 | |
| OPM % | 11% | 17% | 13% | 13% | 7% | 12% | 4.1% | 4.2% | 8% | 12% | 16% | 12% | 14% | |
| Other Income | 4 | 4 | 4 | 4 | 6 | 5 | 0 | -1 | 7 | 2 | 5 | 3 | 7 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | |
| Profit before tax | 9 | 15 | 13 | 14 | 10 | 13 | 1 | -0 | 10 | 11 | 19 | 15 | 22 | |
| Tax % | 15% | 24% | 30% | 24% | 22% | 25% | 4% | 44% | 21% | 26% | 24% | 24% | 24% | |
| Net Profit | 8 | 11 | 9 | 11 | 8 | 10 | 1 | -1 | 8 | 8 | 15 | 11 | 16 | |
| EPS in Rs | 12.64 | 17.76 | 14.41 | 17.56 | 12.67 | 16.25 | 1.26 | -0.84 | 12.37 | 12.79 | 23.86 | 18.37 | 26.63 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.78% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 12 Aug '26◦ |
| Earnings day | +0.78% |
| +1 day | +1.32% |
| +5 days | −11.02% |
| +15 days | −13.73% |
| +30 days | −14.75% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202672.49%Promoter
Promoters72.49%0.24
FIIs0.05%0.02
DIIs0.02%0.02
Public27.43%0.20
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| NGL Fine Chem | ₹2,768.20 | 33.92 | 1,711 | 0.06% | 16 | +115.31% | 137 | +35.54% | 16.69% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts44
PPTAug 2026TranscriptMay 2026PPTMay 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024PPTAug 2024TranscriptJun 2024PPTJun 2024RECJun 2024PPTMay 2024PPTFeb 2024TranscriptNov 2023TranscriptNov 2023PPTNov 2023RECNov 2023PPTAug 2023TranscriptMay 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 16 Sep - One-on-one virtual analyst/investor meet held on September 16, 2026; no presentation and no UPSI shared.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Sep - A One to One meet has been scheduled on Wednesday, September 16, 2026 with Analyst/Investor.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 27 Aug - 45th AGM held on August 25, 2026; all resolutions passed with requisite majority.Shareholder Meeting / Postal Ballot-Outcome of AGM 25 AugCorrigendum To The 45Th Annual Report For The Financial Year 2025-2026 20 Aug - Annual report corrigendum corrects CSR amounts from crores to lakhs; no impact on financial statements.